The Aging Brain and Cognition: Contribution of Vascular Injury, Amyloid Plaque and Tau Protein to Cognitive Dysfunction After Stroke
- Conditions
- Vascular Mild Cognitive ImpairmentPost-stroke Dementia
- Interventions
- Drug: THK-5351
- Registration Number
- NCT04588649
- Lead Sponsor
- Chang Gung Memorial Hospital
- Brief Summary
Stroke can lead to signficiant neurological deficits, and about one-third of stroke patients will be diagnosed of vascular mild cognitive impairment or post-stroke dementia. Post-stroke dementia includes all types of dementia that happen after stroke, irrespective of their cause, and vascular dementia (VaD), degenerative dementia (especially Alzheimer's disease), or mixed dementia (dementia as a result of the coexistence of vascular lesions of the brain and neurodegenerative lesions) are the most common causes of post-stroke dementia. However, it is difficult to determine to what extent cognitive impairment may be attributable to stroke versus concomitant Alzheimer disease. With the advent of PET imaging technique, we are able to conduct a multi-modal neuroimaging study to explore the composite influence of vascular injury, amyloid plaque and Tau protein the the cognitive performance after stroke.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 181
Inclusion criteria for stroke/TIA patients
- Males or females with age >= 50 years old
- Having cerebral stroke or transient ischemic attack
- Modified Rankin Scale < 4
- Ability to participate in cognitive and neuroimaging assessments
- Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
- Provision of signed informed consent
Inclusion criteria for healthy elderly controls
- Males or females with age >= 50 years old
- Without history of cerebral stroke or transient ischemic attack
- Ability to participate in cognitive and neuroimaging assessments
- Female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception after the final study
- Provision of signed informed consent
Exclusion criteria for all subjects
- Presence of dementia diagnosis before the index stroke or at the initial screening History of vascular MCI (VaMCI)
- The Chinese version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) score >=104 [24] at the initial screening.
- Presence of large infarction or lobar encephalomalacia on brain CT or MRI.
- Severe language impairment precluding cognitive assessments, defined as a score of 3 points in the language score of the National Institute of Health Stroke Scale.
- Life expectancy less than 1 year.
- Clinically significant abnormal laboratory values.
- Clinically significant or unstable medical or psychiatric illness.
- Epilepsy history.
- Cognitive impairment resulting from trauma or brain damage.
- Substance abuse or alcoholism in the past 1 year
- General MRI, and / or PET exclusion criteria.
- Pregnant or becoming pregnant during the study (as documented by pregnancy testing at screening or at any date during the study according to the PI discretion) or current breast feeding.
- History of allergy to 18F-labelled radionucleic agents, [18F]AV-45 or [18F]THK-5351.
- Subjects having high risks for the study according to the PI discretion.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description THK-5351 THK-5351 Name: \[18F\]THK5351，(S)-6-\[(3-Fluoro-2-hydroxy)propoxy\]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the tau protein Pharmacological category：Radio pharmaceutical THK-5351 AV-45 Name: \[18F\]THK5351，(S)-6-\[(3-Fluoro-2-hydroxy)propoxy\]-2-(2-Methylaminopyrid-5-yl)-quinoline Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the tau protein Pharmacological category：Radio pharmaceutical AV-45 THK-5351 Name: \[18F\]AV-45, (E)-4-(2-(6-(2-(2-(2-\[18F\]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the β- amyloid protein Pharmacological category：Radio pharmaceutical AV-45 AV-45 Name: \[18F\]AV-45, (E)-4-(2-(6-(2-(2-(2-\[18F\]fluoroethoxy) ethoxy) ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine Dosage form: intravenous injection Dose(s): 10mCi Dosing schedule: Visit 2 Mechanism of action (if known): high affinity radiotracer for the β- amyloid protein Pharmacological category：Radio pharmaceutical
- Primary Outcome Measures
Name Time Method Imaging positive and negative conditions through study completion, an average of 1.5 year PET images are visually assessed by independent raters, who are nuclear medicine doctors and blinded to all clinical and diagnostic information. The raters classify each scan as 0-1 (no significant uptake)、2 (suspicious uptake)、3-4 (significant uptake). The score \>= 2 is deemed as positive condition.
CDR score of cognition deteriorating group and stable group through study completion, an average of 1.5 year The CDR is a 5-point scale (0、0.5、1、2、3) used to characterize six domains of cognitive and functional performance applicable to Alzheimer disease and related dementias: Memory, Orientation, Judgment \& Problem Solving, Community Affairs, Home \& Hobbies, and Personal Care. The necessary information to make each rating is obtained through a semi-structured interview of the patient and a reliable informant or collateral source (e.g., family member).
Global score 0 = Normal、0.5 = Very Mild Dementia、1 = Mild Dementia、2 = Moderate Dementia、3 = Severe Dementia. The cognition deteriorating group is defined as CDR score declines from 0 or 0.5 at Month 3 to \>=1 at Month 18. The cognition stable group is defined as CDR score remains at 0 or 0.5 at Month 18.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Neurology, Chang-Gung memorial Hospital
🇨🇳Taoyuan, Guishan, Taiwan